Ernexa Therapeutics Inc. Warrants financials
$0.0350+11.11%
Close Sep 24, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$4.1M | -$5.6M |
| Net income | -$4.0M | -$5.5M |
| Net margin | — | — |
| Diluted EPS | $-3.40 | $-6.95 |
| EBITDA | -$4.1M | -$3.5M |
| Operating cash flow | -$4.2M | -$2.3M |
| Free cash flow | -$4.2M | -$2.3M |
| Diluted shares | 1.2M | 0.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $5.0M | $9.2M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $6.3M | $10.5M |
| Total liabilities | $3.1M | $3.7M |
| Shareholders' equity | $3.2M | $6.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology